Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671

Structure Therapeutics Inc. (NASDAQ:GPCR) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in.

Structure Therapeutics Inc. (NASDAQ:GPCR) showcased preclinical findings for ACCG-2671 and GSBR-5595 in two late-breaking posters at the ADA 85th Scientific Sessions. ACCG-2671, an oral dual amylin and calcitonin receptor agonist, led to considerable, dose-dependent weight loss in obese rats and improved outcomes when coupled with semaglutide. Clinical studies are anticipated to begin before the end of 2025. A GLP-1 receptor agonist called GSBR-5595 has shown neuroprotective effects in animal models of Parkinson’s disease by enhancing motor function and raising the number of dopaminergic neurons.

Structure Therapeutics To Present Late-Breaking ADA Data on Oral Amylin Agonist ACCG-2671

CEO Raymond Stevens pointed out ACCG-2671’s potential as a distinct oral medication for obesity, citing expanding evidence of amylin receptor targeting. Poster #2184-LB described ACCG-2671’s high binding affinity for human CTR and AMY3R receptors, as well as its synergistic effect with semaglutide in encouraging superior weight reduction. The benefit of GSBR-5595 in Parkinson’s models was noted in Poster #1985-LB, showing that GLP-1 receptor agonists might have many uses. These findings support Structure Therapeutics Inc. (NASDAQ:GPCR)’s plan to provide injectable therapy substitutes with scalable oral small molecules. It is one of the Best Weight Loss Stocks.

READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025.

Disclosure. None.